Peptomyc

Peptomyc is a company dedicated to developing a new generation of cell-penetrating peptides (CPP) targeting the Myc oncogenic protein for cancer treatment. The company was founded in December 2014, based on Dr. Soucek's scientific research on Omomyc (the best direct Myc inhibitor known to date) over the past 20 years.